Molly M. Crenshaw

Molly M. Crenshaw

Auto-generated profile, based on publicly available information

Molly M. Crenshaw

Department of Pediatrics, Section of Clinical Genetics and Metabolism University of Colorado School of Medicine Aurora Colorado USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2023 in Case Reports in Genetics
Verified
Journal Article
Open access
PDF file
MCMolly M. Crenshaw
Molly M. Crenshaw
SGSharon L. Graw
Sharon L. Graw
DSDobromir Slavov
Dobromir Slavov
TBTheresa A. Boyle
Theresa A. Boyle
DPDaniel G. Piqué
Daniel G. Piqué
Peter R. BakerPeter R. Baker
Peter R. Baker
Loss of expression of paternally imprinted genes in the 15q11.2-q13 chromosomal region leads to the neurodevelopmental disorder PraderWilli Syndrome (PWS). The PWS critical region contains four paternally expressed protein-coding genes along with small nucleolar RNA (snoRNA) genes under the control of the SNURF-SNRPN promoter, including the SNORD116 snoRNA gene cluster that is implicated in the PWS disease etiology. A 5-7Mb deletion, maternal uniparental disomy, or an imprinting defect of chromosome 15q affect multiple genes in the PWS critical region, causing PWS. However, the individual contributions of these genes to the PWS phenotype remain elusive. Reports of smaller, atypical deletions may refine the boundaries of the PWS critical region or suggest additional disease-causing mechanisms. We describe an adult female with a classic PWS phenotype due to a 78kb microdeletion that includes only exons 2 and 3 of SNURF-SNRPN with apparently preserved expression of SNORD116.

11 January 2026 in JIMD Reports
Verified
Journal Article
Open access
MCMolly M. Crenshaw
Molly M. Crenshaw
YMYasmeen Midgette
Yasmeen Midgette
SMShruthi Mohan
Shruthi Mohan
RWRuhan Wei
Ruhan Wei
MAMariele Anneling
Mariele Anneling
ASAshlee R. Stiles
Ashlee R. Stiles
Molybdenum cofactor deficiency (MoCD) is an inborn error of metabolism included in the differential for refractory neonatal seizures. The prognosis is guarded, with a median reported age of death between 2.4 and 3.0 years. Mortality is primarily due to seizures and lower respiratory tract infections. MoCD has a distinct biochemical profile, characterized by elevated urinary S ‐sulfocysteine, xanthine, and hypoxanthine, and low or undetectable serum and urine uric acid levels. A disease‐altering treatment is available for MoCD Type A; however, due to the rarity of the condition, its natural history remains poorly understood. We present a patient with neonatal‐onset refractory seizures, whose biochemical testing, performed within 24 h of specimen receipt in the laboratory, revealed a pattern consistent with MoCD. Before the genetics team could disclose the preliminary diagnosis, the patient demised, without evidence of worsening seizures or respiratory infection. Results of genome sequencing, guided by biochemical findings, identified double homozygous pathogenic variants in MOCS1 (associated with MoCD Type A). Although the biochemical genetics laboratory's protocol for analyzing and reporting S ‐sulfocysteine levels within 48 h enabled a rapid preliminary diagnosis, the patient's condition deteriorated too quickly to initiate disease‐altering treatment, progressing more rapidly than described in the literature. We discuss potential hypotheses for his rapid decline and the broader implications for the field of biochemical genetics.

17 August 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
MCMolly M. Crenshaw
Molly M. Crenshaw
LTLauren Thompson
Lauren Thompson
DPDaniel G. Piqué
Daniel G. Piqué
KMKestutis Micke
Kestutis Micke
MSMargarita Saenz
Margarita Saenz
PBPeter R. Baker
Peter R. Baker

23 June 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
MCMolly M. Crenshaw
Molly M. Crenshaw
MMMariana L. Meyers
Mariana L. Meyers
KBKathleen Brown
Kathleen Brown
VSValerie Slegesky
Valerie Slegesky
JDJessica Duis
Jessica Duis
NMNaomi J. L. Meeks
Naomi J. L. Meeks

19 December 2025 in The Clinical Teacher
Verified
Journal Article
Closed access
MCMolly M. Crenshaw
Molly M. Crenshaw
JAJoanne Alfred
Joanne Alfred
CYCheryl Yang
Cheryl Yang
LALauren R. Anderson
Lauren R. Anderson

18 January 2026 in JIMD Reports
Verified
Journal Article
Open access
MCM. M. Crenshaw
M. M. Crenshaw
ODO. M. D'ANnibale
O. M. D'ANnibale
VMV. Martucci
V. Martucci
SGS. Gracie
S. Gracie
AKA. Kochhar
A. Kochhar
MLM. K. LoPiccolo
M. K. LoPiccolo
Hyperammonemia is a medical emergency, and the cause must be identified quickly in order to treat appropriately. Malnutrition is a known risk factor for hyperammonemia; however, there are limited reliable lab indicators used to identify malnutrition. Early identification of the etiology of hyperammonemia is crucial to optimizing care, specifically reintroduction of appropriate amounts of protein into the diet. Herein, we discuss three patients with complex medical histories and clinical signs of malnutrition who presented with hyperammonemia. In all three patients, both hypoaminoacidemia and pyroglutamic aciduria were observed. Specifically, all patients had low tyrosine, tryptophan, methionine, and branched‐chain amino acids. Recognizing this biochemical pattern could result in more rapid initiation of supplementing protein, a primary tenet of treatment in malnutrition‐related hyperammonemia. We highlight the unique features of malnutrition‐related hyperammonemia, propose mechanisms to explain the pattern, and suggest a framework for managing these cases.